Strong growth masked by sharp profit decline and margin compression

Revenue 1437 Cr = 14,370 million, actual 66.9% YoY growth

PAT -7.0% YoY per delivered results

No absolute EBITDA provided; claim of margin expansion unsupported by delivered NPM of 8.3%

Consistent with geographic and brand-level commentary on Nycil/GluconD

Not independently verifiable from delivered results; claims specific but not audited

Q1: ₹80-85Cr annual fixed cost (interest + depreciation) now embedded. Structural change driving profit dilution despite revenue growth. EPS accretive from Q4 FY26 onward; margin accretion expected as revenue scales.

Q1 FY27 domestic +4.6% vs. prior call expectations of stronger momentum. Seasonal brands down 12%, though core brands (Complan, Everyuth, RiteBite) growing double-digit. Prior guidance implied steadier domestic trajectory.

Aspiration 17-18% EBITDA margins maintained, but OPM 16.8%, NPM 8.3% suggest multi-year lag. Prior calls hinted margin expansion imminent via premiumization; now emphasized 'long-term' pipeline (2-3 years).

Organized channel 38% (modern trade 17%, digital 21%), industry-leading. But diversification narrative undermined by -12% seasonal portfolio decline; portfolio still exposed.

24.8% like-for-like this quarter; management restates 'double-digit' aspiration but declined to guide specific growth rate. Comfort Click U.S. entry described as 'very small, growing well'—early stage, not a near-term driver.

No specific constraints. 25% is solid, in line with double-digit guidance we maintain going forward.

Q1 ETR 27% (thin cap rule impact); normalizes to 25% with 12-15% cash component FY27, 25% all-cash FY28. GBP→Euro reduced interest cost; Euro base rate now benchmark, similar run-rate ahead. RiteBite >2x historical growth, driven by brand building, distribution expansion, portfolio enhancement.

Glucon-D: East took biggest hit (continued rains April-May), North/West/South positive. Nycil: North/East (key saliency markets) heavily impacted, West/South grew double-digit. High retail inventory also depressed offtakes. Second half quarter showed recovery; momentum returning.

EPS accretive from Q4 FY26 onward, will continue. If momentum sustains, net margin and EBITDA will increase even in seasonal quarters.

All products OTC, digital-only, no doctor prescription. U.S. entry very small, early stage, growing per expectations. Too early to predict scale, but we're building and positive.

Hard to predict beyond visibility. Own inventory lower than last year. Products have 3-year shelf life, so bad seasons can prolong usage. Consumers buy 1-1.5 packs/season. Already seeing positive growth momentum in recent months. Numbers will play out.

Strong traction, committed resources. Deeper and wider expansion underway. Selective approach—high-value products, top towns still main throughput. Next two class of towns showing good traction. Rural too far for now.

Don't segregate U.K. vs. rest of Europe. Europe has five key markets (U.K., France, Italy, Germany, Spain) forming bulk of business. Overall growth rate captured here. Won't share market-by-market detail.

Consistent approach: segmented Complan into 3-4 segments (core kids, toddler NutriGro, adult VieMax/VieMax Diabetes, RTD Powerplay). Investment in advertising, celebrity (Vaibhav Sooryavanshi), distribution expansion. Multiple formats driving acceptance. Kids nutrition is core driver.

Each category has substantially large possibilities. Driving each with equal conviction. Bars largest today; hard to predict 3 years out.

Core facial cleansing has enough room to grow (scrubs, peel off, face wash). Exploring tan removal, anti-pollution in pipeline. Beyond that, selective exploration (resource constraints). Piloting other spaces. Priority on facial cleansing scalability.

Original products still core drivers. Expanded into newer spaces: wafer bar (millet-based), Roots (ghee/jaggery/dates), Korean chips, RTDs, Max Protein cookies. Each platform sizable. Original + expanded portfolios driving growth; reaching new consumers.

No. Focused on B2C for now.

A&C 18.2% of sales overall (includes Comfort Click, which has higher %). Like-for-like, similar to prior year on core. Digital spend % rising due to consumer media consumption shift; engagements sharper on digital. Spends pivoting to digital.

International 24.8% this quarter (above stated double-digit). Domestic 4.6% (below). Mix: seasonal drag temporary, core brands on track.

Delivered OPM 16.8%, NPM 8.3% vs. aspiration. No specific FY27 target; described as multi-year (2-3 years) objective. Comfort Click accretion, premiumization expected to support.

Distribution expansion commitment (RiteBite T2/T3, quick commerce). Comfort Click U.S./Middle East buildout ongoing. No capex quantum disclosed.

Nycil/GluconD East declined due to unseasonal rains; 12% seasonal portfolio decline. Shelf-life (3 years) prolongs bad-season impact. Recovery dependent on monsoon exit.

Revenue +67% YoY but PAT -7%, suggesting 730bps margin compression. OPM 16.8%, NPM 8.3% vs. 17-18% EBITDA aspiration. Comfort Click amortization ₹24-30Cr masks core profit recovery.

QoQ revenue -3.2%, PAT -26.6%. Sequential decline worse than seasonal headwind alone. Suggests fixed-cost deleverage, working capital timing, or demand cliff.

Consolidated ₹80-85Cr annual fixed cost (interest + depreciation). Amortization of acquired brands ₹24-30Cr embedded, depressing reported PAT. If revenue growth softens, leverage inverts.

Domestic +4.6% YoY, well below historical double-digit expectation. Offset by international growth and premiumization, but core business momentum slower than guided.